ResMed Inc. (NYSE: RMD) Stock Competitors & Peer Comparison
See RMD's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for RMD and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| RMD | $227.67 | +2.10% | 33.3B | 21.32 | $10.77 | +1.06% |
| ISRG | $385.13 | +1.90% | 133.2B | 39.21 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.13% |
| BDX | $184.20 | +0.71% | 51.2B | 14.30 | $13.00 | +2.13% |
| MDLN | $33.50 | +2.78% | 27.2B | 23.53 | $1.36 | N/A |
| WST | $361.98 | +1.91% | 25.7B | 42.93 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $90.53 | +0.79% | 15.6B | 12.69 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.13% |
| BAX | $23.52 | -1.42% | 12.3B | 11.39 | $2.08 | +0.17% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
RMD vs ISRG Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ISRG has a market cap of 133.2B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ISRG trades at $385.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ISRG's P/E ratio is 39.21. In terms of profitability, RMD's ROE is +0.24%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, RMD is less volatile compared to ISRG. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
RMD vs BDXA Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BDXA's P/E ratio is 45.70. In terms of profitability, RMD's ROE is +0.24%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, RMD is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
RMD vs BDX Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BDX has a market cap of 51.2B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BDX trades at $184.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BDX's P/E ratio is 14.30. In terms of profitability, RMD's ROE is +0.24%, compared to BDX's ROE of +0.04%. Regarding short-term risk, RMD is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for RMD.Check BDX's competition here
Medline Inc. (NASDAQ: MDLN)
RMD vs MDLN Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, MDLN has a market cap of 27.2B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while MDLN trades at $33.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas MDLN's P/E ratio is 23.53. In terms of profitability, RMD's ROE is +0.24%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, RMD is less volatile compared to MDLN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
RMD vs WST Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, WST has a market cap of 25.7B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while WST trades at $361.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas WST's P/E ratio is 42.93. In terms of profitability, RMD's ROE is +0.24%, compared to WST's ROE of +0.19%. Regarding short-term risk, RMD is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for RMD.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
RMD vs HOLX Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas HOLX's P/E ratio is 31.54. In terms of profitability, RMD's ROE is +0.24%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, RMD is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for RMD.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
RMD vs SOLV Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, SOLV has a market cap of 15.6B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while SOLV trades at $90.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas SOLV's P/E ratio is 12.69. In terms of profitability, RMD's ROE is +0.24%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, RMD is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
RMD vs BDXB Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BDXB's P/E ratio is 7.60. In terms of profitability, RMD's ROE is +0.24%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, RMD is less volatile compared to BDXB. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
RMD vs BAX Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BAX has a market cap of 12.3B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BAX trades at $23.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BAX's P/E ratio is 11.39. In terms of profitability, RMD's ROE is +0.24%, compared to BAX's ROE of -0.17%. Regarding short-term risk, RMD is less volatile compared to BAX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BAX's competition here
Avantor, Inc. (NYSE: AVTR)
RMD vs AVTR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while AVTR trades at $15.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas AVTR's P/E ratio is 18.15. In terms of profitability, RMD's ROE is +0.24%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, RMD is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for RMD.Check AVTR's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
RMD vs COO Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, COO has a market cap of 10.4B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while COO trades at $54.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas COO's P/E ratio is 11.68. In terms of profitability, RMD's ROE is +0.24%, compared to COO's ROE of +0.07%. Regarding short-term risk, RMD is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check COO's competition here
Repligen Corporation (NASDAQ: RGEN)
RMD vs RGEN Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, RGEN has a market cap of 9.9B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while RGEN trades at $174.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas RGEN's P/E ratio is 97.07. In terms of profitability, RMD's ROE is +0.24%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
RMD vs ATR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ATR has a market cap of 8B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ATR trades at $125.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ATR's P/E ratio is 21.79. In terms of profitability, RMD's ROE is +0.24%, compared to ATR's ROE of +0.14%. Regarding short-term risk, RMD is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
RMD vs BLCO Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BLCO trades at $17.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BLCO's P/E ratio is 26.52. In terms of profitability, RMD's ROE is +0.24%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, RMD is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check BLCO's competition here
Stevanato Group S.p.A. (NYSE: STVN)
RMD vs STVN Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, STVN has a market cap of 5.9B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while STVN trades at $21.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas STVN's P/E ratio is 32.57. In terms of profitability, RMD's ROE is +0.24%, compared to STVN's ROE of +0.09%. Regarding short-term risk, RMD is less volatile compared to STVN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check STVN's competition here
Teleflex Incorporated (NYSE: TFX)
RMD vs TFX Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, TFX has a market cap of 5.7B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while TFX trades at $129.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas TFX's P/E ratio is 14.75. In terms of profitability, RMD's ROE is +0.24%, compared to TFX's ROE of -0.32%. Regarding short-term risk, RMD is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for RMD.Check TFX's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
RMD vs MMSI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while MMSI trades at $86.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas MMSI's P/E ratio is 22.04. In terms of profitability, RMD's ROE is +0.24%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, RMD is less volatile compared to MMSI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check MMSI's competition here
Envista Holdings Corp (NYSE: NVST)
RMD vs NVST Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NVST has a market cap of 4B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NVST trades at $25.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NVST's P/E ratio is 16.85. In terms of profitability, RMD's ROE is +0.24%, compared to NVST's ROE of +0.04%. Regarding short-term risk, RMD is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for RMD.Check NVST's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
RMD vs ICUI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ICUI trades at $158.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ICUI's P/E ratio is 19.46. In terms of profitability, RMD's ROE is +0.24%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, RMD is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ICUI's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
RMD vs PLSE Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, PLSE has a market cap of 3.8B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while PLSE trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas PLSE's P/E ratio is -46.78. In terms of profitability, RMD's ROE is +0.24%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, RMD is less volatile compared to PLSE. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
RMD vs ATRC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ATRC has a market cap of 2.9B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ATRC trades at $56.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ATRC's P/E ratio is 1745.96. In terms of profitability, RMD's ROE is +0.24%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, RMD is less volatile compared to ATRC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ATRC's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
RMD vs XRAY Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, XRAY has a market cap of 2B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while XRAY trades at $10.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas XRAY's P/E ratio is 6.87. In terms of profitability, RMD's ROE is +0.24%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, RMD is less volatile compared to XRAY. This indicates lower risk in terms of short-term price fluctuations for RMD.Check XRAY's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
RMD vs LMAT Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while LMAT trades at $80.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas LMAT's P/E ratio is 29.69. In terms of profitability, RMD's ROE is +0.24%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, RMD is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for RMD.Check LMAT's competition here
BioLife Solutions, Inc. (NASDAQ: BLFS)
RMD vs BLFS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BLFS has a market cap of 1.8B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BLFS trades at $36.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BLFS's P/E ratio is -172.18. In terms of profitability, RMD's ROE is +0.24%, compared to BLFS's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to BLFS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BLFS's competition here
Azenta, Inc. (NASDAQ: AZTA)
RMD vs AZTA Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, AZTA has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while AZTA trades at $33.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas AZTA's P/E ratio is 78.64. In terms of profitability, RMD's ROE is +0.24%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, RMD is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
RMD vs KMTS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, KMTS has a market cap of 1.5B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while KMTS trades at $24.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas KMTS's P/E ratio is -9.50. In terms of profitability, RMD's ROE is +0.24%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, RMD is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
RMD vs STAA Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while STAA trades at $22.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas STAA's P/E ratio is 39.38. In terms of profitability, RMD's ROE is +0.24%, compared to STAA's ROE of +0.01%. Regarding short-term risk, RMD is less volatile compared to STAA. This indicates lower risk in terms of short-term price fluctuations for RMD.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
RMD vs ATRI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ATRI's P/E ratio is 64.50. In terms of profitability, RMD's ROE is +0.24%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, RMD is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
RMD vs ANGO Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ANGO has a market cap of 648.1M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ANGO trades at $15.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ANGO's P/E ratio is -40.21. In terms of profitability, RMD's ROE is +0.24%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, RMD is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ANGO's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
RMD vs SMTI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, SMTI has a market cap of 322.8M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while SMTI trades at $35.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas SMTI's P/E ratio is -585.17. In terms of profitability, RMD's ROE is +0.24%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, RMD is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for RMD.Check SMTI's competition here
Embecta Corp. (NASDAQ: EMBC)
RMD vs EMBC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, EMBC has a market cap of 302M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while EMBC trades at $5.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas EMBC's P/E ratio is 1.96. In terms of profitability, RMD's ROE is +0.24%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, RMD is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check EMBC's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
RMD vs NNNN Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NNNN has a market cap of 241.8M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NNNN trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NNNN's P/E ratio is 79.62. In terms of profitability, RMD's ROE is +0.24%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, RMD is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NNNN's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
RMD vs OSUR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, OSUR has a market cap of 238.2M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while OSUR trades at $3.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas OSUR's P/E ratio is -5.01. In terms of profitability, RMD's ROE is +0.24%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, RMD is more volatile compared to OSUR. This indicates higher risk in terms of short-term price fluctuations for RMD.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
RMD vs UTMD Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, UTMD has a market cap of 237.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while UTMD trades at $74.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas UTMD's P/E ratio is 22.08. In terms of profitability, RMD's ROE is +0.24%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, RMD is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check UTMD's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
RMD vs PDEX Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, PDEX has a market cap of 213.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while PDEX trades at $72.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas PDEX's P/E ratio is 16.20. In terms of profitability, RMD's ROE is +0.24%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, RMD is less volatile compared to PDEX. This indicates lower risk in terms of short-term price fluctuations for RMD.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
RMD vs KRMD Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, KRMD has a market cap of 145.1M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while KRMD trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas KRMD's P/E ratio is -79.00. In terms of profitability, RMD's ROE is +0.24%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, RMD is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for RMD.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
RMD vs STXS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, STXS has a market cap of 129.3M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while STXS trades at $1.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas STXS's P/E ratio is -7.76. In terms of profitability, RMD's ROE is +0.24%, compared to STXS's ROE of -1.33%. Regarding short-term risk, RMD is less volatile compared to STXS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check STXS's competition here
Daxor Corporation (NASDAQ: DXR)
RMD vs DXR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, DXR has a market cap of 68M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while DXR trades at $11.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas DXR's P/E ratio is 9.47. In terms of profitability, RMD's ROE is +0.24%, compared to DXR's ROE of +0.13%. Regarding short-term risk, RMD is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check DXR's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
RMD vs AKYA Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas AKYA's P/E ratio is -1.34. In terms of profitability, RMD's ROE is +0.24%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, RMD is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for RMD.Check AKYA's competition here
SkyAI, Inc. (NASDAQ: STSS)
RMD vs STSS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas STSS's P/E ratio is -0.02. In terms of profitability, RMD's ROE is +0.24%, compared to STSS's ROE of -1.54%. Regarding short-term risk, RMD is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
RMD vs OMIC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas OMIC's P/E ratio is -0.58. In terms of profitability, RMD's ROE is +0.24%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, RMD is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for RMD.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
RMD vs IGAP Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas IGAP's P/E ratio is -10.52. In terms of profitability, RMD's ROE is +0.24%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, RMD is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for RMD.Check IGAP's competition here
Nephros, Inc. (NASDAQ: NEPH)
RMD vs NEPH Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NEPH has a market cap of 46.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NEPH trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NEPH's P/E ratio is 71.50. In terms of profitability, RMD's ROE is +0.24%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, RMD is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NEPH's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
RMD vs POCI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, POCI has a market cap of 46.1M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while POCI trades at $4.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas POCI's P/E ratio is -6.68. In terms of profitability, RMD's ROE is +0.24%, compared to POCI's ROE of -0.37%. Regarding short-term risk, RMD is less volatile compared to POCI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
RMD vs HBIO Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, HBIO has a market cap of 36M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while HBIO trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas HBIO's P/E ratio is -22.17. In terms of profitability, RMD's ROE is +0.24%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, RMD is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for RMD.Check HBIO's competition here
Milestone Scientific Inc. (AMEX: MLSS)
RMD vs MLSS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, MLSS has a market cap of 35.5M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while MLSS trades at $0.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas MLSS's P/E ratio is -8.02. In terms of profitability, RMD's ROE is +0.24%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, RMD is less volatile compared to MLSS. This indicates lower risk in terms of short-term price fluctuations for RMD.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
RMD vs SDC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas SDC's P/E ratio is -0.03. In terms of profitability, RMD's ROE is +0.24%, compared to SDC's ROE of -1.96%. Regarding short-term risk, RMD is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
RMD vs IVC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas IVC's P/E ratio is -0.79. In terms of profitability, RMD's ROE is +0.24%, compared to IVC's ROE of -0.46%. Regarding short-term risk, RMD is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for RMD.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
RMD vs RVP Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, RVP has a market cap of 20.4M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while RVP trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas RVP's P/E ratio is -5.67. In terms of profitability, RMD's ROE is +0.24%, compared to RVP's ROE of -0.05%. Regarding short-term risk, RMD is less volatile compared to RVP. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
RMD vs BNGO Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, BNGO has a market cap of 17.9M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while BNGO trades at $1.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas BNGO's P/E ratio is -0.36. In terms of profitability, RMD's ROE is +0.24%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, RMD is less volatile compared to BNGO. This indicates lower risk in terms of short-term price fluctuations for RMD.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
RMD vs ZJYL Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ZJYL has a market cap of 15.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ZJYL trades at $1.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ZJYL's P/E ratio is 13.61. In terms of profitability, RMD's ROE is +0.24%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, RMD is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
RMD vs RGNT Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, RGNT has a market cap of 12.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while RGNT trades at $1.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas RGNT's P/E ratio is -0.07. In terms of profitability, RMD's ROE is +0.24%, compared to RGNT's ROE of N/A. Regarding short-term risk, RMD is less volatile compared to RGNT. This indicates lower risk in terms of short-term price fluctuations for RMD.Check RGNT's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
RMD vs CUPR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, CUPR has a market cap of 7.9M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while CUPR trades at $1.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas CUPR's P/E ratio is -2.12. In terms of profitability, RMD's ROE is +0.24%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, RMD is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check CUPR's competition here
Femasys Inc. (NASDAQ: FEMY)
RMD vs FEMY Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, FEMY has a market cap of 7.7M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while FEMY trades at $2.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas FEMY's P/E ratio is -0.57. In terms of profitability, RMD's ROE is +0.24%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, RMD is less volatile compared to FEMY. This indicates lower risk in terms of short-term price fluctuations for RMD.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
RMD vs LUCY Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, LUCY has a market cap of 5.2M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while LUCY trades at $0.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas LUCY's P/E ratio is -0.49. In terms of profitability, RMD's ROE is +0.24%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, RMD is less volatile compared to LUCY. This indicates lower risk in terms of short-term price fluctuations for RMD.Check LUCY's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
RMD vs NSTG Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NSTG's P/E ratio is -0.03. In terms of profitability, RMD's ROE is +0.24%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, RMD is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
RMD vs POAI Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas POAI's P/E ratio is -0.03. In terms of profitability, RMD's ROE is +0.24%, compared to POAI's ROE of -21.19%. Regarding short-term risk, RMD is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for RMD.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
RMD vs MHUA Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas MHUA's P/E ratio is 0.25. In terms of profitability, RMD's ROE is +0.24%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, RMD is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for RMD.Check MHUA's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
RMD vs NXGL Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NXGL has a market cap of 2.4M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NXGL trades at $0.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NXGL's P/E ratio is -0.40. In terms of profitability, RMD's ROE is +0.24%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, RMD is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NXGL's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
RMD vs GMVD Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas GMVD's P/E ratio is -0.01. In terms of profitability, RMD's ROE is +0.24%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, RMD is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for RMD.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
RMD vs GMVDW Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas GMVDW's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, RMD is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for RMD.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
RMD vs AVGR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas AVGR's P/E ratio is -0.05. In terms of profitability, RMD's ROE is +0.24%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, RMD is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for RMD.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
RMD vs NXGLW Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, NXGLW has a market cap of 1.2M. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas NXGLW's P/E ratio is -0.02. In terms of profitability, RMD's ROE is +0.24%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, RMD is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for RMD.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
RMD vs LUCYW Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas LUCYW's P/E ratio is N/A. In terms of profitability, RMD's ROE is +0.24%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, RMD is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for RMD.Check LUCYW's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
RMD vs HRC Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, HRC has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas HRC's P/E ratio is 41.92. In terms of profitability, RMD's ROE is +0.24%, compared to HRC's ROE of +0.14%. Regarding short-term risk, RMD is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for RMD.Check HRC's competition here
IntriCon Corporation (NASDAQ: IIN)
RMD vs IIN Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, IIN has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas IIN's P/E ratio is 226.45. In terms of profitability, RMD's ROE is +0.24%, compared to IIN's ROE of -0.00%. Regarding short-term risk, RMD is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for RMD.Check IIN's competition here
Analogic Corporation (NASDAQ: ALOG)
RMD vs ALOG Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ALOG's P/E ratio is 40.93. In terms of profitability, RMD's ROE is +0.24%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, RMD is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ALOG's competition here
Apria, Inc. (NASDAQ: APR)
RMD vs APR Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, APR has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas APR's P/E ratio is 22.59. In terms of profitability, RMD's ROE is +0.24%, compared to APR's ROE of +9.81%. Regarding short-term risk, RMD is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for RMD.Check APR's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
RMD vs ATRS Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas ATRS's P/E ratio is 14.95. In terms of profitability, RMD's ROE is +0.24%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, RMD is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for RMD.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
RMD vs IVTY Comparison September 2026
ResMed Inc. (NYSE: RMD) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, RMD stands at 33.3B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, RMD is priced at $227.67 on the NYSE, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
RMD currently has a P/E ratio of 21.32, whereas IVTY's P/E ratio is -3.80. In terms of profitability, RMD's ROE is +0.24%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, RMD is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for RMD.Check IVTY's competition here